ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss

ADC Therapeutics (NYSE: ADCT) reported Q2 2026 total revenue of $19.2 million, up about 2% from $18.8 million a year earlier, while GAAP loss per share narrowed to $0.11 from $0.50. ZYNLONTA net product revenue remained close to recent-quarter levels, but lower operating expenses substantially reduced the operating and net losses. The main uncertainty is now regulatory: FDA feedback raised concerns about the LOTIS-5 trial’s benefit-risk profile and verification of clinical benefit.

Core earnings data

Net product revenue increased modestly, with the company attributing the change to higher pricing. License revenue and royalties declined to $0.6 million from $0.8 million, limiting total revenue growth.

The more significant change occurred in expenses. Lower R&D and restructuring costs reduced total operating expenses by 29%, while adjusted operating expenses fell 22%.

The adjusted measures exclude items including share-based compensation, restructuring costs, warrant valuation changes and specified financing-related adjustments.

Business and pipeline performance

ZYNLONTA’s commercial performance as a monotherapy in third-line and later diffuse large B-cell lymphoma remained broadly consistent with recent quarters. The product generated $18.6 million in quarterly net revenue, with higher pricing rather than a disclosed volume increase driving the year-over-year gain. Management anticipates growth beginning in 2027 but did not provide quantitative revenue guidance.

Enrollment in the LOTIS-7 Phase 1b trial is complete, with 100 patients enrolled at the selected 150 µg/kg starting dose of ZYNLONTA. The study is evaluating ZYNLONTA with glofitamab in relapsed or refractory DLBCL. Data have been submitted to the ASH annual meeting, and the company plans to submit the combination for Breakthrough Therapy designation in 2026 while assessing a possible Phase 3 trial.

ADC Therapeutics also submitted updated marginal zone lymphoma data to ASH and plans to seek Breakthrough Therapy designation for that indication. Updated follicular lymphoma data are expected to be presented in Q2 2027.

Lower R&D spending outweighed higher commercial costs

R&D expense declined to $17.4 million from $30.1 million. The reduction primarily reflected lower spending on discontinued programs, completion of IND-enabling work for the company’s PSMA-targeting antibody-drug conjugate and the reassignment of certain personnel toward commercial manufacturing and fulfillment activities.

That reassignment shifted some costs rather than eliminating them. Cost of product sales rose to $2.3 million from $0.8 million, including a $1.1 million increase in certain personnel costs. Selling and marketing expense increased to $12.6 million from $10.1 million, while general and administrative expense rose to $9.7 million from $8.8 million.

Restructuring and related costs fell to $2.7 million from $13.1 million. The prior-year figure included severance and a $6.4 million noncash impairment associated with closing the UK facility. Even after excluding restructuring, impairment and share-based compensation, adjusted operating expenses declined by $10.6 million, showing that the improvement was not solely an accounting comparison with the prior restructuring period.

The net loss narrowed more sharply than the operating loss because non-operating items also helped Q2 2026 results. These included income from the change in the fair value of warrant obligations and a cumulative catch-up adjustment related to the deferred royalty obligation.

LOTIS-5 FDA concerns complicate the path to full approval

LOTIS-5 met its primary endpoint of progression-free survival, but feedback from the FDA’s pre-sBLA meeting created a material regulatory issue. The FDA cited substantial concerns about the trial’s benefit-risk profile or verification of clinical benefit, pointing to an imbalance in Grade 5 events in the context of what it characterized as a marginal treatment benefit.

ADC Therapeutics is evaluating the appropriate regulatory path and plans to provide a strategy and timing update. ZYNLONTA remains available under accelerated approval as a monotherapy in third-line and later DLBCL, but the LOTIS-5 feedback creates uncertainty around obtaining full approval through this trial.

LOTIS-7 has consequently become more important to the earlier-line strategy. Management said the ZYNLONTA-glofitamab data support further development and that the safety profile remains generally consistent with previous disclosures. However, complete results have not yet been presented or published, and the company is still assessing the regulatory pathway and a potential Phase 3 study.

Cash position and strategic reorganization

Cash and cash equivalents were $219.1 million on June 30, 2026, down $42.2 million from $261.3 million at the end of 2025, primarily because of cash used in operations. The company expects this cash to provide runway at least into 2028, an estimate that assumes use of the minimum liquidity amount required under its loan covenants.

The balance sheet also included a $299.5 million long-term deferred royalty obligation and approximately $116.6 million of current and long-term senior secured term loans. Shareholders’ deficit widened to $228.2 million from $185.8 million at the end of 2025.

ADC Therapeutics implemented an approximately 17% global workforce reduction and expects about $10 million in annualized savings. The reorganization followed the expected completion of LOTIS-5 and LOTIS-7 and is intended to preserve clinical, regulatory and manufacturing capabilities while maintaining the externally facing commercial and medical affairs organization supporting ZYNLONTA.

Risks investors need to monitor

• Full-approval uncertainty: FDA concerns about LOTIS-5 could affect the route to full approval and create uncertainty around the existing accelerated approval.
• Dependence on ZYNLONTA expansion: Current third-line and later product revenue remains broadly in line with recent quarters, making future growth dependent on regulatory progress, clinical evidence and potential compendia inclusion in additional settings.
• LOTIS-7 execution risk: The company has not yet presented or published complete LOTIS-7 results, and a Phase 3 trial and Breakthrough Therapy designation remain under evaluation or planned.
• Ongoing losses and financial obligations: Cash declined during the first half of 2026, while the company continues to carry substantial deferred royalty and secured loan obligations.
• Reorganization execution: The planned savings must be achieved without weakening the clinical, regulatory, manufacturing and commercial work needed to support ZYNLONTA.

Summary

ADC Therapeutics’ Q2 2026 improvement came primarily from lower spending rather than substantial revenue growth. R&D reductions and lower restructuring charges narrowed the operating loss, while non-operating accounting items further reduced the GAAP net loss. The next major questions are how the company responds to the FDA’s LOTIS-5 concerns, whether LOTIS-7 can support an earlier-line development program and whether the restructuring can extend the cash runway while preserving commercial and regulatory execution.